Island Pharmaceuticals
Biotechnology company focused on repurposing small-molecule antivirals for mosquito-borne and other RNA viral diseases. The company is developing a repurposed oral antiviral candidate for prevention and treatment of dengue and related arboviruses and has progressed clinical development into Phase 2a/2b human challenge studies. The company maintains academic and government collaborations and is exploring expansion of its antiviral pipeline through potential asset acquisition.
Industries
N/A
Nr. of Employees
small (1-50)
Island Pharmaceuticals
Suite 201, 697 Burke Road, Camberwell, Victoria 3124, Australia
Patents
Methods, compositions, and dosing regimens for treatment of SARS-CoV-2 infections
US-12472197-B2
View Details
Methods, compositions, and dosing regimens for treatment of SARS-CoV-2 infections
US-12472197-B2
View DetailsProducts
Repurposed oral antiviral drug candidate for mosquito-borne viruses
An oral small-molecule antiviral candidate repurposed for prevention and treatment of dengue and other mosquito-borne viral infections; advanced into Phase 2a/2b clinical development using a human challenge model.
Pipeline candidate under evaluation (clinical-stage antiviral asset)
Potential addition to the pipeline through due diligence on a clinical-stage broad-spectrum antiviral asset.
Repurposed oral antiviral drug candidate for mosquito-borne viruses
An oral small-molecule antiviral candidate repurposed for prevention and treatment of dengue and other mosquito-borne viral infections; advanced into Phase 2a/2b clinical development using a human challenge model.
Pipeline candidate under evaluation (clinical-stage antiviral asset)
Potential addition to the pipeline through due diligence on a clinical-stage broad-spectrum antiviral asset.
Services
Design and conduct of early- to mid-stage clinical trials for repurposed antiviral small molecules, including human challenge studies with prophylactic and therapeutic cohorts.
Design and conduct of early- to mid-stage clinical trials for repurposed antiviral small molecules, including human challenge studies with prophylactic and therapeutic cohorts.
Expertise Areas
- Clinical trial management (including human challenge trials)
- Antiviral therapeutics development
- Drug repurposing strategies
- Clinical pharmacology and PK analysis
Key Technologies
- Human viral challenge model
- Single ascending dose study design
- Pharmacokinetic (PK) analysis
- Oral small-molecule antiviral development
News & Updates
The company commenced dosing for the Phase 2a/2b human challenge PROTECT study, with the 2a prophylactic cohort dosing and planned 2b therapeutic cohort start.
US FDA cleared an amended protocol to proceed with the Phase 2a/2b trial (PROTECT) in a human challenge model.
Reported pharmacokinetic data from a 24-subject single ascending dose study showing target systemic concentrations after a single dose.
Announced a $3.5 million placement to support ongoing clinical programs and near-term inflection points.
Executive invited as a Rising Star 2024 award winner at the iC3 Life Science & Healthcare Innovation Summit.
The company commenced dosing for the Phase 2a/2b human challenge PROTECT study, with the 2a prophylactic cohort dosing and planned 2b therapeutic cohort start.
US FDA cleared an amended protocol to proceed with the Phase 2a/2b trial (PROTECT) in a human challenge model.
Reported pharmacokinetic data from a 24-subject single ascending dose study showing target systemic concentrations after a single dose.
Announced a $3.5 million placement to support ongoing clinical programs and near-term inflection points.
Executive invited as a Rising Star 2024 award winner at the iC3 Life Science & Healthcare Innovation Summit.